Physician Continuing Medical Education

Accreditation Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, DKBmed, LLC, and Practicing Clinicians Exchange. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

ANCC logo Credit Designation
The Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity for 3.5 contact hour(s) is provided by the Postgraduate Institute for Medicine. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

Release date: April 24, 2017
Expiration date: July 12, 2018
Estimated time to complete activity: 3.5 hours

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Support

This activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:



Dr Michael Robert Clark

Consulting Fees: Depomed, Collegium, Endo Advisory Boards

Ms Yvonne D’Arcy

Consulting Fees: Ortho-McNeil, Purdue-unbranded, Practicing Clinicians Exchange–Chronic Pain, Teva

Fees for Non-CME/CE Services Received Directly From a Commercial Interest or Their Agents: Purdue, Ortho-McNeil-unbranded

Royalty: Lippincott Williams & Wilkins Publishing, Springer Publishing

Dr Bill H. McCarberg

Consulting Fees: Pfizer, Collegium, Takeda, Depomed, AstraZeneca, Daiichi Sankyo, Pernix Therapeutics

Ownership Interest: Johnson & Johnson, BioSpecifics Technologies, Nektar Therapeutics, Galena Biopharma, Collegium

The Planning Committee for this activity included Rachel Deerr and Stan Pogroszewski of DKBmed, LLC. None of the aforementioned members of the Planning Committee have any significant relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Internet Explorer 8.0+ for Windows 2000, 2003, XP, Vista, or Windows 7, 8, or 10
Google Chrome 18.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
Safari 4.0+ for Mac OSX 10.5+